Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
Betty M. Tijms, Eleonora M. Vromen, Olav Mjaavatten, et al.
Nature Aging (2024) Vol. 4, Iss. 1, pp. 33-47
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

Investigating the Neuroprotective and Cognitive-Enhancing Effects of Bacopa monnieri: A Systematic Review Focused on Inflammation, Oxidative Stress, Mitochondrial Dysfunction, and Apoptosis
Luiz José Valotto Neto, Matheus Reverete de Araujo, Renato Cesar Moretti, et al.
Antioxidants (2024) Vol. 13, Iss. 4, pp. 393-393
Open Access | Times Cited: 37
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
Fernándo González‐Ortiz, Bjørn‐Eivind Kirsebom, José Contador, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 21
The concept of resilience to Alzheimer’s Disease: current definitions and cellular and molecular mechanisms
Luuk E. de Vries, Inge Huitinga, Helmut W. Kessels, et al.
Molecular Neurodegeneration (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 21
Proteomic analysis of Alzheimer’s disease cerebrospinal fluid reveals alterations associated with APOE ε4 and atomoxetine treatment
Eric B. Dammer, Anantharaman Shantaraman, Lingyan Ping, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 753
Open Access | Times Cited: 16
The Single Toxin Origin of Alzheimer’s Disease and Other Neurodegenerative Disorders Enables Targeted Approach to Treatment and Prevention
Martin Tolar, John A. Hey, Aidan Power, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2727-2727
Open Access | Times Cited: 9
Zooming in on brain inflammation in Alzheimer’s disease
Wiesje M. van der Flier, Michael T. Heneka
Brain (2025) Vol. 148, Iss. 1, pp. 1-2
Closed Access | Times Cited: 1
Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways
Taekyung Ryu, Kyungdo Kim, Nicholas Asiimwe, et al.
PROTEOMICS (2025)
Open Access | Times Cited: 1
Lanthanide Metal–Organic Framework Flowers for Proteome Profiling and Biomarker Identification in Ultratrace Biofluid Samples
Shuang Zhang, Zhixiao Xu, Youming Chen, et al.
ACS Nano (2025)
Closed Access | Times Cited: 1
Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease
Madia Lozupone, Vittorio Dibello, Rodolfo Sardone, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 6, pp. 639-647
Closed Access | Times Cited: 7
Large-scale Deep Proteomic Analysis in Alzheimer’s Disease Brain Regions Across Race and Ethnicity
Fatemeh Seifar, Edward J. Fox, Anantharaman Shantaraman, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
Crosstalk between bone and brain in Alzheimer's disease: Mechanisms, applications, and perspectives
Zhuo‐Ting Liu, Ming‐Han Liu, Yan Xiong, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 8, pp. 5720-5739
Open Access | Times Cited: 6
C5aR1 antagonism suppresses inflammatory glial responses and alters cellular signaling in an Alzheimer’s disease mouse model
Nicole D. Schartz, Heidi Yahan Liang, Klébea Carvalho, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 6
Alzheimer’s disease and immunotherapy
Wei Qin, Yana Pang, Shuya Nie, et al.
Current Medicine (2024) Vol. 3, Iss. 1
Open Access | Times Cited: 6
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease
B.N. Lizama, H.A. North, Kiran Pandey, et al.
Neurobiology of Disease (2024) Vol. 199, pp. 106575-106575
Open Access | Times Cited: 5
Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies
Aurore Delvenne, Charysse Vandendriessche, Johan Gobom, et al.
Fluids and Barriers of the CNS (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 5
Biofluid specific protein coronas affect lipid nanoparticle behavior in vitro
Demian van Straten, Helena Sork, Luuk van de Schepop, et al.
Journal of Controlled Release (2024) Vol. 373, pp. 481-492
Open Access | Times Cited: 5
Evaluation of cerebrospinal fluid (CSF) and interstitial fluid (ISF) mouse proteomes for the validation and description of Alzheimer’s disease biomarkers
Anna Górska, Irene Santos‐García, Iván Eiriz, et al.
Journal of Neuroscience Methods (2024) Vol. 411, pp. 110239-110239
Open Access | Times Cited: 5
Glial fibrillary acidic protein in Alzheimer’s disease: a narrative review
Florine Leipp, Jérôme Vialaret, Pablo Mohaupt, et al.
Brain Communications (2024) Vol. 6, Iss. 6
Open Access | Times Cited: 5
The choroid plexus: a command center for brain–body communication during inflammation
Huixin Xu, Christine Hehnly, Maria K. Lehtinen
Current Opinion in Immunology (2025) Vol. 93, pp. 102540-102540
Closed Access
Proteomic Subtyping of Alzheimer's Disease CSF links Blood-Brain Barrier Dysfunction to Reduced levels of Tau and Synaptic Biomarkers
Madison C. Bangs, Joshna Gadhavi, Kathleen Carter, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Knowing the enemy: strategic targeting of complement to treat Alzheimer disease
Andrea J. Tenner, Tiffany J. Petrisko
Nature Reviews Neurology (2025)
Closed Access
Current clinical investigations of focused ultrasound blood-brain barrier disruption: A review
Phillip G. Durham, Alexandra Butnariu, Rizk Alghorazi, et al.
Neurotherapeutics (2024) Vol. 21, Iss. 3, pp. e00352-e00352
Open Access | Times Cited: 4
CoVAMPnet: Comparative Markov State Analysis for Studying Effects of Drug Candidates on Disordered Biomolecules
Sérgio M. Marques, Petr Kouba, Anthony Legrand, et al.
JACS Au (2024) Vol. 4, Iss. 6, pp. 2228-2245
Open Access | Times Cited: 4
Post‐GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3
Daniel J. Panyard, Lianne M. Reus, Muhammad Ali, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 7, pp. 5044-5053
Open Access | Times Cited: 4
Neurofilaments and progranulin are related to atrophy in frontotemporal lobar degeneration – A transdiagnostic study cross‐validating atrophy and fluid biomarkers
Lea Hüper, Petra Steinacker, Maryna Polyakova, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 7, pp. 4461-4475
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top